Cytogenetic abnormalities correlate with clinico-biological characteristics in 30 Moroccan multiple myeloma patients

被引:0
作者
Hamdaoui, Hasna [1 ,2 ,3 ]
Nouadi, Badreddine [2 ]
Benlarroubia, Oumaima [3 ]
Chbel, Faiza [4 ]
Saadoune, Chaimaa [2 ]
Lamzouri, Afaf [1 ,5 ]
Chegdani, Fatima [2 ]
机构
[1] Mohammed VI Univ Hosp Ctr, Med Genet & Oncogenet Lab, Tangier, Morocco
[2] Hassan II Univ Casablanca, Fac Sci Ain Chock, Immunol & Biodivers Lab, Casablanca, Morocco
[3] Mohammed VI Univ Hlth Sci UM6SS, Natl Reference Lab, Casablanca, Morocco
[4] Hassan II Univ Casablanca, Ecole Normale Super, Lab Geosci & Mat Engn, Casablanca, Morocco
[5] Abdelmalek Assaadi Univ, Fac Med & Pharm Tangier, Life & Hlth Sci Lab, Tetouan, Morocco
来源
LEUKEMIA RESEARCH REPORTS | 2023年 / 20卷
关键词
Multiple myeloma; Chromosomal abnormalities; Clinic-biological characteristics; Fluorescence in situ hybridization (FISH); GENOMIC ABERRATIONS; EXPRESSION; PROGNOSIS;
D O I
10.1016/j.lrr.2023.100392
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The nonrandom recurrence of chromosomal abnormalities in multiple myeloma (MM) raises the possibility that they play a role in the pathophysiology and development of the disease. Fluorescence in situ hybridization (FISH) can identify a high frequency of certain abnormalities without the need for the proliferative and infiltrative index of malignant plasma cells required for conventional cytogenetic analysis. In this study, we describe the association between clinico-biological characteristics and chromosomal abnormalities in 30 Moroccan patients. Methods: The analysis of cytogenetic data, conventional and molecular, of 30 cases of MM, obtained from our previously cytogenetic study, and correlation of the results with the clinico-biological data of these patients. Results: The bone marrow of 5 of 21 patients (23 %) contained a chromosomally abnormal clone, and all karyotypes were complicated (>3 abnormalities). Interphase FISH (iFISH) has detected aberrations in 14 out of 30 (46 %) of the total cases. The proportion of plasma cells in the bone marrow was higher in patients with chromosomal abnormalities (median 29 %) (p = 0.01917) than in patients without abnormalities (median 11 %). Although there was a difference in the median ss-2 microglobulin percentage (13.8 % versus 6.8 %), it was not statistically significant (p = 0.6818). We also, categorized patients into those with a complex clone and those with a sole abnormality. Patients with high bone marrow plasma cell rate (median 45 %) and high rate of ss-2 microglobulin (median 24 %) showed a complex karyotype and a higher iFISH detection rate than those with plasma cells count for (median 20 %) and ss-2 microglobulin count for (median 11 %) but without statistical significance (p = 0.4338 et p = 0.45 respectively). Furthermore, patients with aberrations had significantly shorter overall survival (100 % for 800 days versus 150 days only). Conclusion: Our research has shown that different subgroups of patients with MM can be classified based on the underlying genetic abnormalities. Chromosomal abnormalities (CA) may give the plasma cell a proliferative advantage, increasing the virulence of the disease and affecting overall survival.
引用
收藏
页数:6
相关论文
共 20 条
[1]   Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project [J].
Avet-Loiseau, H. ;
Durie, B. G. M. ;
Cavo, M. ;
Attal, M. ;
Gutierrez, N. ;
Haessler, J. ;
Goldschmidt, H. ;
Hajek, R. ;
Lee, J. H. ;
Sezer, O. ;
Barlogie, B. ;
Crowley, J. ;
Fonseca, R. ;
Testoni, N. ;
Ross, F. ;
Rajkumar, S. V. ;
Sonneveld, P. ;
Lahuerta, J. ;
Moreau, P. ;
Morgan, G. .
LEUKEMIA, 2013, 27 (03) :711-717
[2]   Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].
Avet-Loiseau, Herve ;
Attal, Michel ;
Moreau, Philippe ;
Charbonnel, Catherine ;
Garban, Frederic ;
Hulin, Cyrille ;
Leyvraz, Serge ;
Michallet, Mauricette ;
Yakoub-Agha, Ibrahim ;
Garderet, Laurent ;
Marit, Gerald ;
Michaux, Lucienne ;
Voillat, Laurent ;
Renaud, Marc ;
Grosbois, Bernard ;
Guillerm, Gaelle ;
Benboubker, Lotfi ;
Monconduit, Mathieu ;
Thieblemont, Catherine ;
Casassus, Philippe ;
Caillot, Denis ;
Stoppa, Anne-Marie ;
Sotto, Jean-Jacques ;
Wetterwald, Marc ;
Dumontet, Charles ;
Fuzibet, Jean-Gabriel ;
Azais, Isabelle ;
Dorvaux, Veronique ;
Zandecki, Marc ;
Bataille, Regis ;
Minvielle, Stephane ;
Harousseau, Jean-Luc ;
Facon, Thierry ;
Mathiot, Claire .
BLOOD, 2007, 109 (08) :3489-3495
[3]  
Bartl R., 1995, Curr. Diagn. Pathol.
[4]   Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 [J].
Chesi, M ;
Nardini, E ;
Brents, LA ;
Schrock, E ;
Ried, T ;
Kuehl, WM ;
Bergsagel, PL .
NATURE GENETICS, 1997, 16 (03) :260-264
[5]   Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma [J].
Debes-Marun, CS ;
Dewald, GW ;
Bryant, S ;
Picken, E ;
Santana-Dávila, R ;
González-Paz, N ;
Winkler, JM ;
Kyle, RA ;
Gertz, MA ;
Witzig, TE ;
Dispenzieri, A ;
Lacy, MQ ;
Rajkumar, SV ;
Lust, JA ;
Greipp, PR ;
Fonseca, R .
LEUKEMIA, 2003, 17 (02) :427-436
[6]   Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].
Fonseca, R ;
Blood, E ;
Rue, M ;
Harrington, D ;
Oken, MM ;
Kyle, RA ;
Dewald, GW ;
Van Ness, B ;
Van Wier, SA ;
Henderson, KJ ;
Bailey, RJ ;
Greipp, PR .
BLOOD, 2003, 101 (11) :4569-4575
[7]   Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients [J].
Hamdaoui, Hasna ;
Benlarroubia, Oumaima ;
Boujmia, Oum Kaltoum Ait ;
Mossafa, Hossein ;
Ouldim, Karim ;
Belkhayat, Aziza ;
Smyej, Imane ;
Benrahma, Houda ;
Dehbi, Hind ;
Chegdani, Fatima .
MOLECULAR GENETICS & GENOMIC MEDICINE, 2020, 8 (09)
[8]   The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time? [J].
Hoellein, Alexander ;
Twardziok, Sven O. ;
Walter, Wencke ;
Hutter, Stephan ;
Baer, Constance ;
Maria Hernandez-Sanchez, Jesus ;
Meggendorfer, Manja ;
Haferlach, Torsten ;
Kern, Wolfgang ;
Haferlach, Claudia .
CANCER GENETICS, 2020, 242 :15-24
[9]  
Kishimoto Renata Kiyomi, 2016, Rev. Bras. Hematol. Hemoter., V38, P113, DOI 10.1016/j.bjhh.2016.01.005
[10]   Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma [J].
Kyle, R. A. ;
Rajkumar, S. V. .
LEUKEMIA, 2009, 23 (01) :3-9